CASI Pharmaceuticals, Inc. (CASI) Earnings History
Annual and quarterly earnings data from 1994 to 2024
Loading earnings history...
CASI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CASI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 39.1% | -138.8% | -137.6% |
| 2023 | 59.2% | -74.0% | -79.5% |
| 2022 | 63.3% | -61.5% | -95.1% |
| 2021 | 58.4% | -137.6% | -121.5% |
| 2020 | 37.2% | -348.6% | -318.9% |
Download Data
Export CASI earnings history in CSV or JSON format
Free sign-in required to download data
CASI Pharmaceuticals, Inc. (CASI) Earnings Overview
As of May 7, 2026, CASI Pharmaceuticals, Inc. (CASI) reported trailing twelve-month net income of -$49M, reflecting -26.7% year-over-year growth. The company earned $-3.08 per diluted share over the past four quarters, with a net profit margin of -137.6%.
Looking at the long-term picture, CASI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2011.
CASI Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ZLAB (-$176M net income, -38.1% margin), LEGN (-$297M net income, -28.8% margin), ZYME (-$81M net income, -76.6% margin), CASI has room to improve margins relative to the peer group. Compare CASI vs ZLAB →
CASI Earnings vs Peers
Earnings metrics vs comparable public companies
CASI Historical Earnings Data (1994–2024)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$39M | -45.7% | -$40M | $-2.56 | -137.6% | -138.8% |
| 2023 | -$27M | +34.3% | -$25M | $-2.02 | -79.5% | -74.0% |
| 2022 | -$41M | -11.9% | -$26M | $-3.01 | -95.1% | -61.5% |
| 2021 | -$37M | +24.1% | -$42M | $-2.69 | -121.5% | -137.6% |
| 2020 | -$48M | -6.4% | -$53M | $-4.37 | -318.9% | -348.6% |
| 2019 | -$45M | -65.1% | -$40M | $-4.80 | -1098.1% | -968.1% |
| 2018 | -$27M | -155.1% | -$27M | $-3.24 | - | - |
| 2017 | -$11M | -13.9% | -$11M | $-1.75 | - | - |
| 2016 | -$9M | -31.2% | $9M | $-1.69 | - | - |
| 2015 | -$7M | +72.5% | $7M | $-2.22 | -15104.0% | 14990.8% |
See CASI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CASI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CASI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCASI — Frequently Asked Questions
Quick answers to the most common questions about buying CASI stock.
Is CASI growing earnings?
CASI EPS fell to $-3.08, with earnings declining -26.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-49M.
What are CASI's profit margins?
CASI Pharmaceuticals, Inc. net margin is -137.6%, with operating margin at -138.8%. Below-average margins reflect competitive or cost pressures.
How consistent are CASI's earnings?
CASI earnings data spans 1994-2024. The declining earnings trend is -26.7% YoY. Historical data enables comparison across business cycles.